Daiichi Sankyo

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Sosei Heptares has developed considerable expertise in GPCRs that has allowed it to attract a string of partners, with Genentech joining Pfizer, AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo, amongst others.

Research charity LifeArc cashes $1.2bn royalty from Keytruda

In March it formed a cancer immunotherapy alliance with CRUK and Ono Pharma, in April it licensed an ion channel drug discovery programme to Daiichi Sankyo, and in early May it

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

separately gave Daiichi Sankyo some succour by backing pexidartinib for a rare condition called tenosynovial giant cell tumour (TGCT). ... tissues. Daiichi Sankyo acquired the drug when it bought Taiwanese firm Plexxikon for almost $1bn in 2011.

Pfizer’s alliance with Sosei Heptares bears first fruit

Pfizer is just one of Sosei Heptares’ big pharma partners, and the company has also attracted sizeable collaborations with AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

Pivotal phase 2 data backs investment. AstraZeneca has the positive pivotal trial it needed to justify its big investment in Daiichi’s HER2-targeting antibody-drug conjugate DS-8201, a rival ... There are no anti-HER2 therapies currently approved for

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]